Further, the combined application of trastuzumab (monoclonal antibody targeting HER2) and HER2 vaccine showed better effects in treating HER2+ breast cancer patients vs. trastuzumab or HER2 vaccine treatment alone (29). The gene discussed is ERBB2; the disease is breast carcinoma.